<?xml version="1.0" encoding="UTF-8"?>
<!-- This sitemap was dynamically generated on 18.04.2026 at 8:02 pm by All in One SEO v4.9.5.1 - the original SEO plugin for WordPress. -->

<?xml-stylesheet type="text/xsl" href="https://cq-platform.com/default-sitemap.xsl"?>

<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
	<channel>
		<title>Cq-Platform</title>
		<link><![CDATA[https://cq-platform.com]]></link>
		<description><![CDATA[Cq-Platform]]></description>
		<lastBuildDate><![CDATA[Sun, 18 Jan 2026 23:47:01 +0000]]></lastBuildDate>
		<docs>https://validator.w3.org/feed/docs/rss2.html</docs>
		<atom:link href="https://cq-platform.com/sitemap.rss" rel="self" type="application/rss+xml" />
		<ttl><![CDATA[60]]></ttl>

		<item>
			<guid><![CDATA[https://cq-platform.com/]]></guid>
			<link><![CDATA[https://cq-platform.com/]]></link>
			<title>Gateway</title>
			<pubDate><![CDATA[Sun, 18 Jan 2026 23:47:01 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cq-platform.com/blog/]]></guid>
			<link><![CDATA[https://cq-platform.com/blog/]]></link>
			<title>Blog</title>
			<pubDate><![CDATA[Sun, 11 May 2025 16:42:55 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cq-platform.com/quizzes/treatment-protocols/]]></guid>
			<link><![CDATA[https://cq-platform.com/quizzes/treatment-protocols/]]></link>
			<title>Treatment protocols</title>
			<pubDate><![CDATA[Fri, 17 Apr 2026 20:25:24 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cq-platform.com/questions/in-the-management-of-hypertensive-patients-with-ckd-and-a-gfr-between-30-and-60-ml-min-what-is-the-protocol-regarding-ace-inhibitors-acei-or-arbs/]]></guid>
			<link><![CDATA[https://cq-platform.com/questions/in-the-management-of-hypertensive-patients-with-ckd-and-a-gfr-between-30-and-60-ml-min-what-is-the-protocol-regarding-ace-inhibitors-acei-or-arbs/]]></link>
			<title>In the management of hypertensive patients with CKD and a GFR between 30 and 60 mL/min, what is the protocol regarding ACE inhibitors (ACEi) or ARBs?</title>
			<pubDate><![CDATA[Fri, 17 Apr 2026 20:24:33 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cq-platform.com/questions/which-immunosuppressive-agent-is-recommended-as-an-alternative-induction-phase-treatment-for-class-iii-iv-lupus-nephritis-especially-in-patients-concerned-about-the-toxicity-of-cyclophosphamide/]]></guid>
			<link><![CDATA[https://cq-platform.com/questions/which-immunosuppressive-agent-is-recommended-as-an-alternative-induction-phase-treatment-for-class-iii-iv-lupus-nephritis-especially-in-patients-concerned-about-the-toxicity-of-cyclophosphamide/]]></link>
			<title>Which immunosuppressive agent is recommended as an alternative induction phase treatment for Class III/IV Lupus Nephritis, especially in patients concerned about the toxicity of Cyclophosphamide?</title>
			<pubDate><![CDATA[Fri, 17 Apr 2026 20:23:32 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cq-platform.com/questions/for-a-patient-with-iga-nephropathy-who-exhibits-slowly-progressive-renal-impairment-and-persistent-proteinuria-despite-blood-pressure-control-which-therapeutic-trial-is-recommended-2/]]></guid>
			<link><![CDATA[https://cq-platform.com/questions/for-a-patient-with-iga-nephropathy-who-exhibits-slowly-progressive-renal-impairment-and-persistent-proteinuria-despite-blood-pressure-control-which-therapeutic-trial-is-recommended-2/]]></link>
			<title>For a patient with IgA Nephropathy who exhibits &#8220;slowly progressive renal impairment&#8221; and persistent proteinuria despite blood pressure control, which therapeutic trial is recommended?</title>
			<pubDate><![CDATA[Fri, 17 Apr 2026 20:22:41 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cq-platform.com/questions/for-a-patient-with-iga-nephropathy-who-exhibits-slowly-progressive-renal-impairment-and-persistent-proteinuria-despite-blood-pressure-control-which-therapeutic-trial-is-recommended/]]></guid>
			<link><![CDATA[https://cq-platform.com/questions/for-a-patient-with-iga-nephropathy-who-exhibits-slowly-progressive-renal-impairment-and-persistent-proteinuria-despite-blood-pressure-control-which-therapeutic-trial-is-recommended/]]></link>
			<title>For a patient with IgA Nephropathy who exhibits &#8220;slowly progressive renal impairment&#8221; and persistent proteinuria despite blood pressure control, which therapeutic trial is recommended?</title>
			<pubDate><![CDATA[Fri, 17 Apr 2026 20:22:31 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cq-platform.com/questions/what-is-the-recommended-management-approach-for-a-child-with-typical-uncomplicated-post-streptococcal-glomerulonephritis-psgn/]]></guid>
			<link><![CDATA[https://cq-platform.com/questions/what-is-the-recommended-management-approach-for-a-child-with-typical-uncomplicated-post-streptococcal-glomerulonephritis-psgn/]]></link>
			<title>What is the recommended management approach for a child with typical, uncomplicated Post-streptococcal Glomerulonephritis (PSGN)?</title>
			<pubDate><![CDATA[Fri, 17 Apr 2026 20:21:23 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cq-platform.com/questions/which-monoclonal-antibody-targets-the-cd20-antigen-on-b-lymphocytes-and-is-utilized-in-patients-with-lupus-nephritis-who-are-refractory-to-conventional-induction-therapies/]]></guid>
			<link><![CDATA[https://cq-platform.com/questions/which-monoclonal-antibody-targets-the-cd20-antigen-on-b-lymphocytes-and-is-utilized-in-patients-with-lupus-nephritis-who-are-refractory-to-conventional-induction-therapies/]]></link>
			<title>Which monoclonal antibody targets the CD20 antigen on B lymphocytes and is utilized in patients with Lupus Nephritis who are refractory to conventional induction therapies?</title>
			<pubDate><![CDATA[Fri, 17 Apr 2026 20:19:48 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cq-platform.com/questions/regarding-the-treatment-of-focal-segmental-glomerulosclerosis-fsgs-which-of-the-following-is-true-based-on-the-clinical-protocols-provided/]]></guid>
			<link><![CDATA[https://cq-platform.com/questions/regarding-the-treatment-of-focal-segmental-glomerulosclerosis-fsgs-which-of-the-following-is-true-based-on-the-clinical-protocols-provided/]]></link>
			<title>Regarding the treatment of Focal Segmental Glomerulosclerosis (FSGS), which of the following is true based on the clinical protocols provided?</title>
			<pubDate><![CDATA[Fri, 17 Apr 2026 20:18:36 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cq-platform.com/questions/when-treating-anemia-in-a-patient-with-chronic-kidney-disease-ckd-using-erythropoiesis-stimulating-agents-esas-physicians-are-cautioned-not-to-use-them-to-maintain-hemoglobin-hb-levels-above-wh/]]></guid>
			<link><![CDATA[https://cq-platform.com/questions/when-treating-anemia-in-a-patient-with-chronic-kidney-disease-ckd-using-erythropoiesis-stimulating-agents-esas-physicians-are-cautioned-not-to-use-them-to-maintain-hemoglobin-hb-levels-above-wh/]]></link>
			<title>When treating anemia in a patient with Chronic Kidney Disease (CKD) using Erythropoiesis-Stimulating Agents (ESAs), physicians are cautioned not to use them to maintain Hemoglobin (Hb) levels above which threshold?</title>
			<pubDate><![CDATA[Fri, 17 Apr 2026 20:17:34 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cq-platform.com/questions/in-a-patient-diagnosed-with-membranoproliferative-glomerulonephritis-mpgn-that-is-secondary-to-chronic-hepatitis-c-infection-what-is-the-clinical-management-priority/]]></guid>
			<link><![CDATA[https://cq-platform.com/questions/in-a-patient-diagnosed-with-membranoproliferative-glomerulonephritis-mpgn-that-is-secondary-to-chronic-hepatitis-c-infection-what-is-the-clinical-management-priority/]]></link>
			<title>In a patient diagnosed with Membranoproliferative Glomerulonephritis (MPGN) that is secondary to Chronic Hepatitis C infection, what is the clinical management priority?</title>
			<pubDate><![CDATA[Fri, 17 Apr 2026 20:15:53 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cq-platform.com/questions/which-lifestyle-modification-is-identified-as-a-fundamental-sign-of-proper-management-for-the-edema-associated-with-nephrotic-syndrome-3/]]></guid>
			<link><![CDATA[https://cq-platform.com/questions/which-lifestyle-modification-is-identified-as-a-fundamental-sign-of-proper-management-for-the-edema-associated-with-nephrotic-syndrome-3/]]></link>
			<title>Which lifestyle modification is identified as a fundamental sign of proper management for the edema associated with Nephrotic Syndrome?</title>
			<pubDate><![CDATA[Fri, 17 Apr 2026 20:14:08 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cq-platform.com/questions/which-lifestyle-modification-is-identified-as-a-fundamental-sign-of-proper-management-for-the-edema-associated-with-nephrotic-syndrome-2/]]></guid>
			<link><![CDATA[https://cq-platform.com/questions/which-lifestyle-modification-is-identified-as-a-fundamental-sign-of-proper-management-for-the-edema-associated-with-nephrotic-syndrome-2/]]></link>
			<title>Which lifestyle modification is identified as a fundamental sign of proper management for the edema associated with Nephrotic Syndrome?</title>
			<pubDate><![CDATA[Fri, 17 Apr 2026 20:11:38 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cq-platform.com/questions/which-lifestyle-modification-is-identified-as-a-fundamental-sign-of-proper-management-for-the-edema-associated-with-nephrotic-syndrome/]]></guid>
			<link><![CDATA[https://cq-platform.com/questions/which-lifestyle-modification-is-identified-as-a-fundamental-sign-of-proper-management-for-the-edema-associated-with-nephrotic-syndrome/]]></link>
			<title>Which lifestyle modification is identified as a fundamental sign of proper management for the edema associated with Nephrotic Syndrome?</title>
			<pubDate><![CDATA[Fri, 17 Apr 2026 20:11:21 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cq-platform.com/questions/class-vi-lupus-nephritis-is-histologically-characterized-by-global-sclerosis-involving-what-percentage-of-the-glomeruli-indicating-that-treatment-should-shift-toward-renal-replacement-therapy-rrt/]]></guid>
			<link><![CDATA[https://cq-platform.com/questions/class-vi-lupus-nephritis-is-histologically-characterized-by-global-sclerosis-involving-what-percentage-of-the-glomeruli-indicating-that-treatment-should-shift-toward-renal-replacement-therapy-rrt/]]></link>
			<title>Class VI Lupus Nephritis is histologically characterized by global sclerosis involving what percentage of the glomeruli, indicating that treatment should shift toward Renal Replacement Therapy (RRT)?</title>
			<pubDate><![CDATA[Fri, 17 Apr 2026 20:09:48 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cq-platform.com/questions/what-is-the-physiological-rationale-for-prescribing-ace-inhibitors-or-arbs-to-patients-with-glomerular-disease-who-have-significant-proteinuria/]]></guid>
			<link><![CDATA[https://cq-platform.com/questions/what-is-the-physiological-rationale-for-prescribing-ace-inhibitors-or-arbs-to-patients-with-glomerular-disease-who-have-significant-proteinuria/]]></link>
			<title>What is the physiological rationale for prescribing ACE inhibitors or ARBs to patients with glomerular disease who have significant proteinuria?</title>
			<pubDate><![CDATA[Fri, 17 Apr 2026 19:58:18 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cq-platform.com/questions/when-utilizing-alkylating-agents-e-g-cyclophosphamide-for-multirelapsing-or-steroid-resistant-minimal-change-disease-what-is-the-standard-recommended-duration-of-the-oral-course/]]></guid>
			<link><![CDATA[https://cq-platform.com/questions/when-utilizing-alkylating-agents-e-g-cyclophosphamide-for-multirelapsing-or-steroid-resistant-minimal-change-disease-what-is-the-standard-recommended-duration-of-the-oral-course/]]></link>
			<title>When utilizing Alkylating agents (e.g., Cyclophosphamide) for multirelapsing or steroid-resistant Minimal Change Disease, what is the standard recommended duration of the oral course?</title>
			<pubDate><![CDATA[Fri, 17 Apr 2026 19:53:45 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cq-platform.com/questions/cyclosporine-a-csa/]]></guid>
			<link><![CDATA[https://cq-platform.com/questions/cyclosporine-a-csa/]]></link>
			<title>Cyclosporine A (CsA)</title>
			<pubDate><![CDATA[Fri, 17 Apr 2026 19:49:22 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cq-platform.com/questions/which-therapeutic-agent-is-preferred-for-managing-minimal-change-disease-in-patients-where-corticosteroids-are-contraindicated-such-as-those-at-high-risk-for-diabetes-or-osteonecrosis-2/]]></guid>
			<link><![CDATA[https://cq-platform.com/questions/which-therapeutic-agent-is-preferred-for-managing-minimal-change-disease-in-patients-where-corticosteroids-are-contraindicated-such-as-those-at-high-risk-for-diabetes-or-osteonecrosis-2/]]></link>
			<title>Which therapeutic agent is preferred for managing Minimal Change Disease in patients where corticosteroids are contraindicated, such as those at high risk for diabetes or osteonecrosis?</title>
			<pubDate><![CDATA[Fri, 17 Apr 2026 19:49:22 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cq-platform.com/questions/which-therapeutic-agent-is-preferred-for-managing-minimal-change-disease-in-patients-where-corticosteroids-are-contraindicated-such-as-those-at-high-risk-for-diabetes-or-osteonecrosis/]]></guid>
			<link><![CDATA[https://cq-platform.com/questions/which-therapeutic-agent-is-preferred-for-managing-minimal-change-disease-in-patients-where-corticosteroids-are-contraindicated-such-as-those-at-high-risk-for-diabetes-or-osteonecrosis/]]></link>
			<title>Which therapeutic agent is preferred for managing Minimal Change Disease in patients where corticosteroids are contraindicated, such as those at high risk for diabetes or osteonecrosis?</title>
			<pubDate><![CDATA[Fri, 17 Apr 2026 19:48:52 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cq-platform.com/questions/in-membranous-nephropathy-mn-what-timeframe-of-conservative-treatment-monitoring-and-supportive-care-is-generally-advised-for-patients-with-moderate-proteinuria-before-escalating-to-immunosup/]]></guid>
			<link><![CDATA[https://cq-platform.com/questions/in-membranous-nephropathy-mn-what-timeframe-of-conservative-treatment-monitoring-and-supportive-care-is-generally-advised-for-patients-with-moderate-proteinuria-before-escalating-to-immunosup/]]></link>
			<title>In Membranous Nephropathy (MN), what timeframe of &#8220;conservative treatment&#8221; (monitoring and supportive care) is generally advised for patients with moderate proteinuria before escalating to immunosuppressive therapy?</title>
			<pubDate><![CDATA[Fri, 17 Apr 2026 19:47:47 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cq-platform.com/questions/which-pharmacological-intervention-is-considered-reno-protective-and-should-be-initiated-in-all-patients-with-diabetes-and-microalbuminuria-even-if-their-blood-pressure-is-currently-within-the-no/]]></guid>
			<link><![CDATA[https://cq-platform.com/questions/which-pharmacological-intervention-is-considered-reno-protective-and-should-be-initiated-in-all-patients-with-diabetes-and-microalbuminuria-even-if-their-blood-pressure-is-currently-within-the-no/]]></link>
			<title>Which pharmacological intervention is considered &#8220;reno-protective&#8221; and should be initiated in all patients with Diabetes and Microalbuminuria, even if their blood pressure is currently within the normal range?</title>
			<pubDate><![CDATA[Fri, 17 Apr 2026 19:46:35 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cq-platform.com/questions/in-the-induction-phase-of-treatment-for-aggressive-lupus-nephritis-class-iii-or-iv-which-of-the-following-is-identified-as-a-primary-recommended-regimen/]]></guid>
			<link><![CDATA[https://cq-platform.com/questions/in-the-induction-phase-of-treatment-for-aggressive-lupus-nephritis-class-iii-or-iv-which-of-the-following-is-identified-as-a-primary-recommended-regimen/]]></link>
			<title>In the induction phase of treatment for aggressive Lupus Nephritis (Class III or IV), which of the following is identified as a primary recommended regimen?</title>
			<pubDate><![CDATA[Fri, 17 Apr 2026 19:44:56 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cq-platform.com/questions/according-to-the-provided-sources-what-is-the-gold-standard-treatment-protocol-for-the-management-of-type-i-rapidly-progressive-glomerulonephritis-anti-gbm-disease-goodpasture-syndrome/]]></guid>
			<link><![CDATA[https://cq-platform.com/questions/according-to-the-provided-sources-what-is-the-gold-standard-treatment-protocol-for-the-management-of-type-i-rapidly-progressive-glomerulonephritis-anti-gbm-disease-goodpasture-syndrome/]]></link>
			<title>According to the provided sources, what is the &#8220;Gold Standard&#8221; treatment protocol for the management of Type I Rapidly Progressive Glomerulonephritis (Anti-GBM disease/Goodpasture Syndrome)?</title>
			<pubDate><![CDATA[Fri, 17 Apr 2026 19:43:43 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cq-platform.com/questions/for-a-patient-with-iga-nephropathy-igan-and-persistent-proteinuria-what-is-the-specific-target-blood-pressure-recommended-by-clinical-guidelines-to-slow-renal-progression/]]></guid>
			<link><![CDATA[https://cq-platform.com/questions/for-a-patient-with-iga-nephropathy-igan-and-persistent-proteinuria-what-is-the-specific-target-blood-pressure-recommended-by-clinical-guidelines-to-slow-renal-progression/]]></link>
			<title>For a patient with IgA Nephropathy (IgAN) and persistent proteinuria, what is the specific target blood pressure recommended by clinical guidelines to slow renal progression?</title>
			<pubDate><![CDATA[Fri, 17 Apr 2026 19:41:57 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cq-platform.com/questions/in-adult-patients-with-minimal-change-disease-mcd-what-is-the-standard-first-line-induction-protocol-for-oral-prednisone-to-achieve-complete-remission/]]></guid>
			<link><![CDATA[https://cq-platform.com/questions/in-adult-patients-with-minimal-change-disease-mcd-what-is-the-standard-first-line-induction-protocol-for-oral-prednisone-to-achieve-complete-remission/]]></link>
			<title>In adult patients with Minimal Change Disease (MCD), what is the standard first-line induction protocol for oral Prednisone to achieve complete remission?</title>
			<pubDate><![CDATA[Fri, 17 Apr 2026 19:39:53 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cq-platform.com/quizzes/diagnosis-urinalysis-serology-renal-biopsy/]]></guid>
			<link><![CDATA[https://cq-platform.com/quizzes/diagnosis-urinalysis-serology-renal-biopsy/]]></link>
			<title>Diagnosis: urinalysis, serology, renal biopsy</title>
			<pubDate><![CDATA[Fri, 17 Apr 2026 18:56:21 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cq-platform.com/questions/according-to-the-sources-when-is-a-renal-biopsy-typically-indicated-in-a-child-with-a-nephrotic-range-proteinuria/]]></guid>
			<link><![CDATA[https://cq-platform.com/questions/according-to-the-sources-when-is-a-renal-biopsy-typically-indicated-in-a-child-with-a-nephrotic-range-proteinuria/]]></link>
			<title>According to the sources, when is a renal biopsy typically indicated in a child with a nephrotic-range proteinuria?</title>
			<pubDate><![CDATA[Fri, 17 Apr 2026 17:55:41 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cq-platform.com/questions/in-lupus-nephritis-which-combination-of-serological-markers-is-most-strongly-associated-with-an-active-renal-flare/]]></guid>
			<link><![CDATA[https://cq-platform.com/questions/in-lupus-nephritis-which-combination-of-serological-markers-is-most-strongly-associated-with-an-active-renal-flare/]]></link>
			<title>In Lupus Nephritis, which combination of serological markers is most strongly associated with an active renal flare?</title>
			<pubDate><![CDATA[Fri, 17 Apr 2026 17:54:53 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cq-platform.com/questions/what-is-the-clinical-purpose-of-the-addis-count-in-a-laboratory-setting/]]></guid>
			<link><![CDATA[https://cq-platform.com/questions/what-is-the-clinical-purpose-of-the-addis-count-in-a-laboratory-setting/]]></link>
			<title>What is the clinical purpose of the &#8220;Addis Count&#8221; in a laboratory setting?</title>
			<pubDate><![CDATA[Fri, 17 Apr 2026 17:54:08 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cq-platform.com/questions/histologically-the-crescents-found-in-rapidly-progressive-glomerulonephritis-are-composed-of-a-proliferation-of/]]></guid>
			<link><![CDATA[https://cq-platform.com/questions/histologically-the-crescents-found-in-rapidly-progressive-glomerulonephritis-are-composed-of-a-proliferation-of/]]></link>
			<title>Histologically, the &#8220;crescents&#8221; found in Rapidly Progressive Glomerulonephritis are composed of a proliferation of:</title>
			<pubDate><![CDATA[Fri, 17 Apr 2026 17:53:21 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cq-platform.com/questions/which-statement-regarding-serology-in-iga-nephropathy-is-correct/]]></guid>
			<link><![CDATA[https://cq-platform.com/questions/which-statement-regarding-serology-in-iga-nephropathy-is-correct/]]></link>
			<title>Which statement regarding serology in IgA Nephropathy is correct?</title>
			<pubDate><![CDATA[Fri, 17 Apr 2026 17:52:32 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cq-platform.com/questions/which-specialized-stain-used-in-light-microscopy-of-a-renal-biopsy-is-best-for-visualizing-the-glomerular-basement-membrane-and-detecting-spikes/]]></guid>
			<link><![CDATA[https://cq-platform.com/questions/which-specialized-stain-used-in-light-microscopy-of-a-renal-biopsy-is-best-for-visualizing-the-glomerular-basement-membrane-and-detecting-spikes/]]></link>
			<title>Which specialized stain used in light microscopy of a renal biopsy is best for visualizing the glomerular basement membrane and detecting &#8220;spikes&#8221;?</title>
			<pubDate><![CDATA[Fri, 17 Apr 2026 17:50:49 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cq-platform.com/questions/why-is-a-standard-urinary-dipstick-considered-an-unreliable-tool-for-screening-proteinuria-in-patients-with-multiple-myeloma/]]></guid>
			<link><![CDATA[https://cq-platform.com/questions/why-is-a-standard-urinary-dipstick-considered-an-unreliable-tool-for-screening-proteinuria-in-patients-with-multiple-myeloma/]]></link>
			<title>Why is a standard urinary dipstick considered an unreliable tool for screening proteinuria in patients with Multiple Myeloma?</title>
			<pubDate><![CDATA[Fri, 17 Apr 2026 17:49:57 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cq-platform.com/questions/which-of-the-following-is-an-absolute-contraindication-for-a-percutaneous-renal-biopsy/]]></guid>
			<link><![CDATA[https://cq-platform.com/questions/which-of-the-following-is-an-absolute-contraindication-for-a-percutaneous-renal-biopsy/]]></link>
			<title>Which of the following is an absolute contraindication for a percutaneous renal biopsy?</title>
			<pubDate><![CDATA[Fri, 17 Apr 2026 17:48:20 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cq-platform.com/questions/in-post-streptococcal-glomerulonephritis-what-is-the-typical-latency-period-between-the-initial-pharyngeal-infection-and-the-onset-of-the-nephritic-syndrome/]]></guid>
			<link><![CDATA[https://cq-platform.com/questions/in-post-streptococcal-glomerulonephritis-what-is-the-typical-latency-period-between-the-initial-pharyngeal-infection-and-the-onset-of-the-nephritic-syndrome/]]></link>
			<title>In Post-streptococcal Glomerulonephritis, what is the typical latency period between the initial pharyngeal infection and the onset of the nephritic syndrome?</title>
			<pubDate><![CDATA[Fri, 17 Apr 2026 17:47:31 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cq-platform.com/questions/under-electron-microscopy-em-which-finding-is-diagnostic-for-minimal-change-disease-mcd/]]></guid>
			<link><![CDATA[https://cq-platform.com/questions/under-electron-microscopy-em-which-finding-is-diagnostic-for-minimal-change-disease-mcd/]]></link>
			<title>Under Electron Microscopy (EM), which finding is diagnostic for Minimal Change Disease (MCD)?</title>
			<pubDate><![CDATA[Fri, 17 Apr 2026 17:46:42 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cq-platform.com/questions/a-patient-with-rapidly-progressive-renal-failure-and-a-positive-c-anca-anti-proteinase-3-titer-most-likely-has/]]></guid>
			<link><![CDATA[https://cq-platform.com/questions/a-patient-with-rapidly-progressive-renal-failure-and-a-positive-c-anca-anti-proteinase-3-titer-most-likely-has/]]></link>
			<title>A patient with rapidly progressive renal failure and a positive c-ANCA (anti-proteinase 3) titer most likely has:</title>
			<pubDate><![CDATA[Fri, 17 Apr 2026 17:45:57 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cq-platform.com/questions/in-the-context-of-the-liquid-biopsy-urinalysis-what-quantitative-threshold-of-proteinuria-is-required-for-a-diagnosis-of-nephrotic-syndrome-in-an-adult/]]></guid>
			<link><![CDATA[https://cq-platform.com/questions/in-the-context-of-the-liquid-biopsy-urinalysis-what-quantitative-threshold-of-proteinuria-is-required-for-a-diagnosis-of-nephrotic-syndrome-in-an-adult/]]></link>
			<title>In the context of the &#8220;liquid biopsy&#8221; (urinalysis), what quantitative threshold of proteinuria is required for a diagnosis of Nephrotic Syndrome in an adult?</title>
			<pubDate><![CDATA[Fri, 17 Apr 2026 17:44:59 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cq-platform.com/questions/what-is-the-standard-post-procedural-protocol-for-manual-compression-and-positioning-following-a-renal-biopsy-to-prevent-perirenal-hematoma/]]></guid>
			<link><![CDATA[https://cq-platform.com/questions/what-is-the-standard-post-procedural-protocol-for-manual-compression-and-positioning-following-a-renal-biopsy-to-prevent-perirenal-hematoma/]]></link>
			<title>What is the standard post-procedural protocol for manual compression and positioning following a renal biopsy to prevent perirenal hematoma?</title>
			<pubDate><![CDATA[Fri, 17 Apr 2026 17:43:39 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cq-platform.com/questions/when-evaluating-hypocomplementemia-in-glomerulonephritis-a-profile-showing-low-c3-but-normal-c4-suggests-activation-of-which-pathway/]]></guid>
			<link><![CDATA[https://cq-platform.com/questions/when-evaluating-hypocomplementemia-in-glomerulonephritis-a-profile-showing-low-c3-but-normal-c4-suggests-activation-of-which-pathway/]]></link>
			<title>When evaluating hypocomplementemia in glomerulonephritis, a profile showing low C3 but normal C4 suggests activation of which pathway?</title>
			<pubDate><![CDATA[Fri, 17 Apr 2026 17:42:38 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cq-platform.com/questions/which-laboratory-technique-is-identified-as-indispensable-for-the-definitive-diagnosis-of-iga-nephropathy/]]></guid>
			<link><![CDATA[https://cq-platform.com/questions/which-laboratory-technique-is-identified-as-indispensable-for-the-definitive-diagnosis-of-iga-nephropathy/]]></link>
			<title>Which laboratory technique is identified as &#8220;indispensable&#8221; for the definitive diagnosis of IgA Nephropathy?</title>
			<pubDate><![CDATA[Fri, 17 Apr 2026 17:41:37 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cq-platform.com/questions/which-term-describes-a-urinary-sediment-where-red-blood-cells-white-blood-cells-and-multiple-varieties-of-casts-granular-waxy-etc-are-present-simultaneously-often-seen-in-aggressive-lupus-neph/]]></guid>
			<link><![CDATA[https://cq-platform.com/questions/which-term-describes-a-urinary-sediment-where-red-blood-cells-white-blood-cells-and-multiple-varieties-of-casts-granular-waxy-etc-are-present-simultaneously-often-seen-in-aggressive-lupus-neph/]]></link>
			<title>Which term describes a urinary sediment where red blood cells, white blood cells, and multiple varieties of casts (granular, waxy, etc.) are present simultaneously, often seen in aggressive Lupus Nephritis?</title>
			<pubDate><![CDATA[Fri, 17 Apr 2026 17:40:45 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cq-platform.com/questions/in-a-patient-suspected-of-having-goodpasture-syndrome-type-i-rpgn-the-pathognomonic-serological-finding-involves-antibodies-directed-against/]]></guid>
			<link><![CDATA[https://cq-platform.com/questions/in-a-patient-suspected-of-having-goodpasture-syndrome-type-i-rpgn-the-pathognomonic-serological-finding-involves-antibodies-directed-against/]]></link>
			<title>In a patient suspected of having Goodpasture Syndrome (Type I RPGN), the pathognomonic serological finding involves antibodies directed against:</title>
			<pubDate><![CDATA[Fri, 17 Apr 2026 17:39:51 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cq-platform.com/questions/during-an-ultrasound-guided-renal-biopsy-the-physician-targets-the-lower-pole-of-the-kidney-cortical-tissue-primarily-to/]]></guid>
			<link><![CDATA[https://cq-platform.com/questions/during-an-ultrasound-guided-renal-biopsy-the-physician-targets-the-lower-pole-of-the-kidney-cortical-tissue-primarily-to/]]></link>
			<title>During an ultrasound-guided renal biopsy, the physician targets the &#8220;lower pole&#8221; of the kidney cortical tissue primarily to:</title>
			<pubDate><![CDATA[Fri, 10 Apr 2026 17:51:56 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cq-platform.com/questions/which-serological-marker-is-considered-highly-specific-for-the-diagnosis-of-primary-idiopathic-membranous-nephropathy-in-adults/]]></guid>
			<link><![CDATA[https://cq-platform.com/questions/which-serological-marker-is-considered-highly-specific-for-the-diagnosis-of-primary-idiopathic-membranous-nephropathy-in-adults/]]></link>
			<title>Which serological marker is considered highly specific for the diagnosis of primary (idiopathic) Membranous Nephropathy in adults?</title>
			<pubDate><![CDATA[Fri, 10 Apr 2026 17:51:06 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cq-platform.com/questions/a-microscopic-urinalysis-reveals-the-presence-of-acanthocytes-dysmorphic-red-blood-cells-this-finding-is-a-specific-indicator-of-which-of-the-following/]]></guid>
			<link><![CDATA[https://cq-platform.com/questions/a-microscopic-urinalysis-reveals-the-presence-of-acanthocytes-dysmorphic-red-blood-cells-this-finding-is-a-specific-indicator-of-which-of-the-following/]]></link>
			<title>A microscopic urinalysis reveals the presence of &#8220;acanthocytes&#8221; (dysmorphic red blood cells). This finding is a specific indicator of which of the following?</title>
			<pubDate><![CDATA[Fri, 10 Apr 2026 17:50:05 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cq-platform.com/quizzes/rapidly-progressive-glomerulonephritis/]]></guid>
			<link><![CDATA[https://cq-platform.com/quizzes/rapidly-progressive-glomerulonephritis/]]></link>
			<title>Rapidly progressive glomerulonephritis</title>
			<pubDate><![CDATA[Fri, 10 Apr 2026 17:47:12 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cq-platform.com/questions/which-age-groups-show-a-peak-incidence-for-goodpasture-syndrome/]]></guid>
			<link><![CDATA[https://cq-platform.com/questions/which-age-groups-show-a-peak-incidence-for-goodpasture-syndrome/]]></link>
			<title>Which age group(s) show a peak incidence for Goodpasture Syndrome?</title>
			<pubDate><![CDATA[Fri, 10 Apr 2026 17:46:26 +0000]]></pubDate>
		</item>
				</channel>
</rss>
